Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$9.18 USD
+0.08 (0.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.19 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHAT 9.18 +0.08(0.88%)
Will PHAT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
3 Top Breakout Stocks Worth a Buy for Attractive Returns
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?
Other News for PHAT
Buy Rating Justified by Strong Market Acceptance of Phathom Pharmaceuticals’ V oquezna
Commit To Buy Phathom Pharmaceuticals At $7.50, Earn 28.2% Annualized Using Options
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Buy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V oquezna
Analysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)